Why did Eli Lilly acquire Merida Biosciences for up to $2.875 billion?

Eli Lilly’s Merida deal is framed as a platform bet in autoimmune disease, aimed at gaining a foothold in selectively degrading pathogenic autoantibodies. The article says that differentiated mechanism, rather than a conventional single asset add-on, is the main strategic rationale highlighted in the source summary.